富祥药业(300497.SZ)：上半年净亏损691.12万元

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 515 million yuan, representing a year-on-year decrease of 24.58% [1] - The net profit attributable to shareholders of the listed company was -6.91 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -32.18 million yuan [1] - Basic earnings per share were -0.01 yuan [1]